[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613517":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":24,"locations":30,"responsibleParty":111,"collaborators":114,"id":129,"slug":130,"hasResults":131,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":131,"sex":137,"minAge":138,"maxAge":12,"enrollmentInfo":139,"targetDuration":12,"studyType":142,"phases":143,"briefSummary":145,"conditions":146,"keywords":152,"overallStatus":159,"whyStopped":12,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":169},{"fullName":5,"class":6},"University Hospital, Geneva","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Group","NO_INTERVENTION","Care in the control group is based on international guidelines for the management of VAP and carried out in accordance with the local guidelines of each center. This includes respiratory samples with traditional cultures to identify pathogens associated with VAP.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Intervention Group","EXPERIMENTAL","In the intervention arm, in addition to traditional cultures for identifying pathogens and their resistance, multiplex PCR will be performed on the patient's respiratory samples. Empirical antibiotic therapy will be directly adapted to the results of multiplex PCR according to the guidelines provided.",[18],"Device: PCR multiplex BioFire Pneumonia plus",[20],{"type":21,"name":22,"description":16,"armGroupLabels":23,"otherNames":12},"DEVICE","PCR multiplex BioFire Pneumonia plus",[14],[25],{"name":26,"role":27,"phone":28,"phoneExt":12,"email":29},"Christophe Le Terrier, MD","CONTACT","+41795532741","christophe.leterrier@hug.ch",[31,52,68,82,95],{"facility":32,"status":12,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"University hospitals of Geneva, Division of Intensive Care","Geneva","Canton of Geneva","1205","Switzerland","CH",{"type":39,"coordinates":40},"Point",[41,42],6.14569,46.20222,{"lat":42,"lon":41},[45,47,49],{"name":26,"role":27,"phone":46,"phoneExt":12,"email":29},"+795532741",{"name":26,"role":48,"phone":12,"phoneExt":12,"email":12},"PRINCIPAL_INVESTIGATOR",{"name":50,"role":51,"phone":12,"phoneExt":12,"email":12},"Vivian Valiton","SUB_INVESTIGATOR",{"facility":53,"status":12,"city":54,"state":12,"zip":12,"country":36,"countryCode":37,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"Dept. of Intensive Care Medicine, University hospital of Lausanne","Lausanne",{"type":39,"coordinates":56},[57,58],6.63282,46.516,{"lat":58,"lon":57},[61,65,66],{"name":62,"role":27,"phone":63,"phoneExt":12,"email":64},"Jean-Daniel CHICHE, MD, PhD","+41 79 5562393","Jean-Daniel.Chiche@chuv.ch",{"name":62,"role":48,"phone":12,"phoneExt":12,"email":12},{"name":67,"role":51,"phone":12,"phoneExt":12,"email":12},"Jean-Luc PAGANI, MD",{"facility":69,"status":12,"city":70,"state":12,"zip":12,"country":36,"countryCode":37,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Division of Intensive care, Hospital of Lugano","Lugano",{"type":39,"coordinates":72},[73,74],8.96004,46.01008,{"lat":74,"lon":73},[77,81],{"name":78,"role":27,"phone":79,"phoneExt":12,"email":80},"Alberto Pagnamenta, MD","+41 91 811 64 82","Alberto.Pagnamenta@eoc.ch",{"name":78,"role":48,"phone":12,"phoneExt":12,"email":12},{"facility":83,"status":12,"city":84,"state":12,"zip":12,"country":36,"countryCode":37,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Division of Intensive care, Hospital of Neuchâtel","Neuchâtel",{"type":39,"coordinates":86},[87,88],6.931,46.99179,{"lat":88,"lon":87},[91,94],{"name":92,"role":27,"phone":93,"phoneExt":12,"email":12},"Marie-Eve Brunner, MD","+41327133450",{"name":92,"role":48,"phone":12,"phoneExt":12,"email":12},{"facility":96,"status":12,"city":97,"state":12,"zip":12,"country":36,"countryCode":37,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Division of Intensive care, University hospital of Sion","Sion",{"type":39,"coordinates":99},[100,101],7.35559,46.22739,{"lat":101,"lon":100},[104,108,109],{"name":105,"role":27,"phone":106,"phoneExt":12,"email":107},"Juan José García Martínez, MD","+4127 60 38357","JuanJose.GarciaMartinez@hopitalvs.ch",{"name":105,"role":48,"phone":12,"phoneExt":12,"email":12},{"name":110,"role":51,"phone":12,"phoneExt":12,"email":12},"Stéphane Emonet, MD, PhD",{"type":48,"investigatorFullName":112,"investigatorTitle":113,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"Christophe Le Terrier","Investigator coordinator and Attending Physician in ICU",[115,118,121,123,125,127],{"name":116,"class":117},"BioMérieux","INDUSTRY",{"name":119,"class":120},"Hospital Fribourg, Switzerland","UNKNOWN",{"name":122,"class":120},"Hôpital universitaire de Lausanne",{"name":124,"class":120},"Hospital of Neuchâtel",{"name":126,"class":6},"Centre Hospitalier du Centre du Valais",{"name":128,"class":120},"Hospital Lugano","100613517","early-antibiotics-adaptation-in-severe-pneumoniathe-early-adapt-study-100613517",false,"NCT07267624","EARLY Antibiotics aDAptation in Severe Pneumonia(The EARLY ADAPT Study)","EARLY Antibiotics aDaptation in Ventilator-Acquired-Pneumonia Treatment After Implementation of a Broad-Panel Respiratory Multiplex PCR Test: A Multicenter Randomized Control Trial Conducted In Swiss Intensive Care Units. The EARLY ADAPT Study.","EARLY ADAPT","Inclusion Criteria:\n\n* Adult patients (≥ 18 years old)\n* Hospitalized in intensive care with invasive mechanical ventilation ≥ 48 hours\n* Administration of antimicrobial therapy for suspected VAP at the time of inclusion.\n* Expected survival \\> 96 hours.\n\nExclusion Criteria:\n\n* Enrollment prior to the current trial\n* Participation in an interventional study on the management of AMR that has a direct impact on antibiotic therapy practices.","ALL","18 Years",{"count":140,"type":141},170,"ESTIMATED","INTERVENTIONAL",[144],"NA","The objective of the study is to determine whether rapid multiplex PCR testing of respiratory samples can reduce exposure to broad-spectrum antibiotics in intensive care unit patients with suspected or confirmed ventilator-associated pneumonia, compared to standard diagnostic methods.\n\nAs secondary objectives, the investigators will study antibiotic management and overall antibiotic consumption, as well as escalation or de-escalation events. The investigators will study the potential clinical impact of using multiplex PCR to see if the length of stay in the intensive care unit is reduced, as well as the duration of mechanical ventilation.",[147,148,149,150,151],"VAP - Ventilator Associated Pneumonia","Antibiotic","Antibiotic Stewardship","Antibiotic Prescribing for Acute Respiratory-tract Infections","Intensive Care (ICU)",[153,154,155,156,157,158],"ventilator Associated Pneumonia (VAP)","antibiotic","PCR multiplex","intensive care","broad spectrum antibiotic","stewardship","NOT_YET_RECRUITING","2026-04-28",{"date":162,"type":163},"2026-04-29","ACTUAL",{"date":165,"type":141},"2026-06-05",{"date":167,"type":141},"2028-06-30",{"name":5,"class":6},5]